Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 15,100 shares, an increase of 6.3% from the April 15th total of 14,200 shares. Based on an average daily volume of 25,400 shares, the […]
Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the target of a large growth in short interest in July. As of July 31st, there was short interest totalling 19,700 shares, a growth of 8.2% from the July 15th total of 18,200 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average […]
- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave.
Adagene Inc. (NASDAQ:ADAG – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 14,600 shares, an increase of 44.6% from the March 15th total of 10,100 shares. Approximately 0.0% of the shares of the stock are sold short. […]